ClinicalTrials.gg

Program

TJ102

A development code.

Its studies are mostly in Ovarian Neoplasms, led by Phrontline Biopharma.

Furthest: phase 2, since Aug 9, 20261 company-led study, 1 open or runningNext primary completion: Sep 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Phrontline Biopharma11 open or runningphase 2since Aug 9, 2026Aug 9, 2026Sep 2029phase 2 · NCT07778498

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 9, 2026First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT07778498 · 150 planned · United States, China

Ahead

  1. Sep 2029Primary completion: phase 2 study in Ovarian NeoplasmsNCT07778498

TargetBeta

CDH6 →read by rule
“TJ102 is a CDH6/FRa directed antibody conjugate with dual payloads”study text, by rule · the study

Other programs on CDH6

ProgramCompanyFurthest phaseStudies
raludotatug deruxtecanMerckphase 311
Anti-CDH6 Antibody-drug Conjugate SIM0505rulenextcure-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07778498Ovarian Neoplasms · United States, China2RecruitingSep 2029150

How it is read

Names in the registry

  • “TJ102”, 1 entry

Codes read as this program: TJ102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.